Congenital factor XIII deficiency with multiple connective tissue tumours and successful pregnancy with substitutive therapy (a case report)

1992 ◽  
Vol 3 (6) ◽  
pp. 810
Author(s):  
Z. Boda ◽  
G. Pfliegler ◽  
L. Muszbek ◽  
A. T??th ◽  
R. ??d??ny ◽  
...  
1987 ◽  
Vol 55 (1) ◽  
pp. 45-48 ◽  
Author(s):  
F. Rodeghiero ◽  
G. C. Castaman ◽  
E. Bona ◽  
M. Ruggeri ◽  
E. Dini

2019 ◽  
Vol 85 ◽  
pp. S82-S83
Author(s):  
S. Karaman ◽  
A. Unuvar ◽  
D. Tugcu ◽  
F. Bilgili ◽  
S. Genc ◽  
...  

1989 ◽  
Vol 19 (6) ◽  
pp. 348-352 ◽  
Author(s):  
Z. Boda ◽  
G. Pfliegler ◽  
L. Muszbek ◽  
A. Tóth ◽  
R. Ádány ◽  
...  

2021 ◽  
Vol 43 ◽  
pp. S53-S54
Author(s):  
İbrahim Eker ◽  
Yeter Düzenli Kar ◽  
Nilgün Eroğlu ◽  
Özge Vural ◽  
Mehmet Yılmazer

1968 ◽  
Vol 20 (03/04) ◽  
pp. 534-541 ◽  
Author(s):  
O Egeberg

SummarySevere hemorrhagic disorder due to congenital factor XIII deficiency is described in two unrelated Norwegian girls.Plasma cephalin time was for both patients extraordinarily short during episodes of bleeding and hematomas. No such hyperactivity reaction was demonstrable in unaffected condition some months later.Estimations of blood factor XIII levels revealed a partial defect in the parents of both children, and also in some other family members, consistent with an autosomal incompletely recessive inheritance of the defect. Some of the presumptive heterozygotes had a history of light bleeding phenomenons; whether this was related to their partial lack of factor XIII is so far uncertain.


2020 ◽  
Author(s):  
Jingjing Han ◽  
Miao Jiang ◽  
Jian Su ◽  
Ziqiang Yu ◽  
Xia Bai ◽  
...  

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hoda Motlagh ◽  
Akbar Dorgalaleh ◽  
Shadi Tabibian ◽  
Majid Naderi ◽  
Farhad Zaker

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Gianluca Sottilotta ◽  
Francesca Luise ◽  
Vincenzo Oriana ◽  
Angela Piromalli ◽  
Rosa Santacroce ◽  
...  

Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by heaviness and pain) performed in a patient with FXIII deficiency, receiving recombinant FXIII prophylaxis (Catridecacog 35 UI/kg every 28±2 days). Our experience shows that Catridecacog can be used safely and effectively not only for continued prophylaxis but also in surgery and adds to the very limited body of evidence currently available on surgery in this bleeding disorder.


Sign in / Sign up

Export Citation Format

Share Document